Filtered By:
Source: Cellular and Molecular Neurobiology
Condition: Hemorrhagic Stroke
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3 results found since Jan 2013.
Modulation of α7nAchR by Melatonin Alleviates Ischemia and Reperfusion-Compromised Integrity of Blood-Brain Barrier Through Inhibiting HMGB1-Mediated Microglia Activation and CRTC1-Mediated Neuronal Loss
Cell Mol Neurobiol. 2021 Jul 1. doi: 10.1007/s10571-021-01122-2. Online ahead of print.ABSTRACTThe only food and drug administration (FDA)-approved drug currently available for the treatment of acute ischemic stroke is tissue plasminogen activator (tPA), yet the therapeutic benefits of this drug are partially outweighed by the increased risk of hemorrhagic transformation (HT). Analysis of the NIH trial has shown that cigarette smoking protected tPA-treated patients from HT; however, the underlying mechanism is not clear. Nicotinic acetylcholine receptors (nAChR) has shown anti-inflammatory effect and modulation nAChR could...
Source: Cellular and Molecular Neurobiology - July 1, 2021 Category: Cytology Authors: Shuang Chen Yanyun Sun Fei Li Xinyu Zhang Xiaoyan Hu Xiaoyun Zhao Yixuan Li Hui Li Jianliang Zhang Wenlan Liu Guo-Qing Zheng Xinchun Jin Source Type: research
